<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GEMTUZUMAB OZOGAMICIN</span><br/>(gem-tu'zu-mab)<br/><span class="topboxtradename">Mylotarg<br/></span><b>Classifications:</b> <span class="classification"> immunosuppressant</span>; <span class="classification">monoclonal antibody</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Chemotherapeutic agent composed of recombinant IgG antibodies which binds specifically to the CD33 antigens.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cytotoxic to the CD33 positive human leukemia cells in the bone marrow found on the surface of leukemic cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of CD33 positive acute myeloid leukemia (AML) in first relapse in patients <img src="../images/special/greaterorequal.gif"/>60
         y.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gemtuzumab or anti-CD33 antibody therapy, systemic infections; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment; renal dysfunction; moderate or severe thrombocytopenia or neutropenia. History of asthma or allergies;
         concurrent administration with antiplatelet agents or anticoagulants.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Myeloid Leukemia (AML)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 9 mg/m<sup>2</sup> infused over 2 h, repeat in 14 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Protect gemtuzumab from sunlight and unshielded fluorescent light during preparation and administration.</li>
<li>Allow vials to come to room temperature before reconstitution.</li>
<li>Acetaminophen 650 mg orally and diphenhydramine 2550 mg IV are normally given prior to infusion to control adverse effects.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Reconstitute each vial with 5 mL of sterile water for injection to yield 1 mg/mL. Gently swirl to dissolve. Dilute the reconstituted
                  drug further just prior to administration by withdrawing the required amount of drug and adding it to 100 mL of NS. Cover
                  the IV bag with a UV protectant cover.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Infuse over 2 h through a separate IV line with a nonpyrogenic low-protein-binding 1.2 micron filter. Do not give push as
                  a bolus dose.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive &amp;:</span> <span class="incompattype">Y-site:</span> Do not mix with other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials refrigerated at 2°8° C (36°46° F). Store reconstituted drug refrigerated
            at 2°8° C (36°46° F) and protected for light for <img src="../images/special/lesserorequal.gif"/>8
            h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Severe hypersensitivity <span class="speceff-common">anaphylaxis, chills, fever, asthenia, infection, sepsis</span>. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension,</span> hypertension, tachycardia. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, mucositis, abdominal pain, anorexia, constipation, diarrhea, stomatitis.</span> <span class="typehead">Hematologic:</span> <span class="speceff-life"> <i>Neutropenia, thrombocytopenia, anemia</i> </span>, <span class="speceff-common">bleeding,</span> epistaxis, cerebral hemorrhage, hematuria, ecchymosis. <span class="typehead">Metabolic:</span> Hyperglycemia, <span class="speceff-common">hyperbilirubinemia,</span> abnormal AST, ALT, hypokalemia, hypomagnesemia, increased lactic dehydrogenase. <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> depression, dizziness, <span class="speceff-common">insomnia.</span> <span class="typehead">Respiratory:</span> Hypoxia, <span class="speceff-common">dyspnea, cough,</span> pharyngitis, rhinitis, pneumonia, <span class="speceff-common">fatal pulmonary events.</span> <span class="typehead">Skin:</span> <span class="speceff-common">Rash, herpes simplex, local reactions from infusion, peripheral edema, petechiae.</span>
<h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Hydrolyzed in liver to calicheamicin. <span class="typehead">Half-Life:</span> 45100 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of postinfusion syndrome: fever, chills, and rigors which occur 24 h after initiation of infusion; hypotension
            and dyspnea which may occur during first 24 h after infusion.
         </li>
<li>Monitor vital signs during and for at least 2 h after infusion.</li>
<li>Lab tests: Monitor CBC with differential, platelet count, lymphoblast smears at least weekly. Periodically monitor liver functions
            and routine blood chemistry.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report S&amp;S of infection immediately to physician (e.g., chills, fever, sore throat, lower back or side pain).</li>
<li>Report unusual bleeding or bruising, black tarry stools, or pinpoint red spots on skin to physician immediately.</li>
<li>Avoid exposure to infections.</li>
<li>Avoid immunizations unless approved by physician; avoid contact with anyone who has received oral polio virus vaccine.</li>
<li>Avoid situations that could result in injury during periods of bone marrow suppression.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>